Camurus AB (publ)

Camurus AB (publ), founded in 1991 and headquartered in Lund, Sweden, is a pharmaceutical firm focused on the creation and commercialization of medications for severe and persistent illnesses. Its market reach extends across Europe, Australia, the United States, Japan, and other international territories. The company's current product offerings include Buvidal, an injectable buprenorphine formulation used to manage opioid dependence, and Brixadi, also prescribed for opioid use disorder. Additionally, it markets episil oral liquid, a medical device designed to treat painful and inflammatory conditions affecting the oral cavity. Camurus maintains an active development pipeline featuring several investigational therapies. These include CAM2038 for chronic pain, and CAM2029, which is progressing through Phase III clinical trials for acromegaly and neuroendocrine tumors, alongside Phase II studies for polycystic liver diseases. CAM2043 is currently in Phase I trials for pulmonary arterial hypertension and Phase II for Raynaud's phenomenon. Further programs encompass CAM2032 (Phase II for prostate cancer), CAM4072 (Phase III for genetic obesity disorders), CAM4071 (Phase I for an endocrine disorder), CAM2047 (Phase I for chemotherapy-induced nausea and vomiting), and CAM2048 (Phase I for postoperative pain).

Camurus AB (publ) trades as CAMX.ST on STO. The company is classified in Healthcare / Drug Manufacturers - Specialty & Generic and reports in SEK.

The current profile places the business in Drug Manufacturers - Specialty & Generic. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Detailed operating-segment data is not available for this symbol yet.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Camurus AB (publ) can be compared against peers such as Active Biotech AB (publ), AddLife AB (publ), Asker Healthcare Group AB, BioArctic AB (publ), Genovis AB (publ.), Mendus AB (publ).

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $31.87B, beta of 0.39, and return on equity of N/A.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

CAMX.ST currently shows total debt of N/A and beta of 0.39. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.camurus.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.